Últimas noticias sobre Corsair Gaming (NASDAQ:CRSR) Bolsa

Corsair Gaming

Corsair Gaming Inc is engaged in the business of providing high-performance gear for gamers and content creators. The product portfolio includes Cases, Keyboards, Mice, Headsets, Power Supplies, Gaming Computers, Gaming Chairs, Mousepads, and other related products. The company operates in two segments namely, Gamer and Creator peripherals, which is the key revenue-generating segment; and Gaming Components and Systems. Geographically, the group derives revenue from the Americas, Europe and the Middle East, and the Asia Pacific.

Corsair Gaming Inc

Argus Research analyst John Staszak maintains Restaurant Brands Intl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QSR#NYSE">QSR</a>) with a Buy and lowers the price target from $85 to $80.

News

Price Target

Analyst Ratings

Argus Research Maintains Buy on Restaurant Brands Intl, Lowers Price Target to $80

DA Davidson analyst Rudy Kessinger maintains Fastly (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FSLY#NYSE">FSLY</a>) with a Neutral and raises the price target from $5.5 to $7.5.

FSLY

DA Davidson Maintains Neutral on Fastly, Raises Price Target to $7.5

On Thursday, Emergent BioSolutions Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EBS#NYSE">EBS</a>) stock is trading higher on mixed third-quarter earnings and a new mpox trial in Africa.
The company reported third-quarter sales of $293.8 million, up 9% year over year, with the management guidance of $265&nbsp;million–$315 million, and missing the&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">consensus of $297.5 million</a>.
The company reported an adjusted EPS of $1.37, a turnaround from a loss of $1.09 a year ago,&nbsp;beating <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/g41786475/emergent-biosolutions-reports-third-quarter-2024-financial-results" rel="noreferrer noopener">the consensus of $0.14</a>.
Revenues from Narcan&nbsp;(naloxone HCl) Nasal Spray decreased 33% to $95.3 million, primarily driven by the discontinuation of prescription Narcan&nbsp;due to the launch of over-the-counter Narcan&nbsp;in the third quarter of 2023 and lower Canadian retail sales, partially offset by higher sales of OTC Narcan.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/09/41026819/emergent-biosolutions-confirms-orders-worth-400m-related-to-smallpox-mpox-vaccines" rel="noreferrer noopener">Emergent BioSolutions Confirms Orders Worth $400M Related To Smallpox, Mpox Vaccines</a>
Revenues from Anthrax MCM fell 65% to $11.4 million, and Smallpox MCM sales jumped more than fivefold to $132.7 million.
Guidance: Emergent BioSolutions updated its 2024 revenue guidance from $1.05 billion &#8211; $1.125 billion to $1.065 billion &#8211; $1.125 billion, compared to the consensus of $1.123 billion.
The updated guidance includes commercial product sales of $420&nbsp;million &#8211;&nbsp;$430 million compared to <a target="_blank" href="https://www.benzinga.com/general/biotech/24/08/40226161/vaccine-maker-emergent-biosolutions-expects-deeper-losses-in-2024-stock-sinks" rel="noreferrer noopener">prior guidance of </a>$450 million – $480 million.
MCM Product sales outlook of $510&nbsp;million &#8211; $550 million, compared to $455&nbsp;million – $490 million expected earlier.
Services segment sales are expected to be $105&nbsp;million &#8211; $110 million, lower than the prior range of $120&nbsp;million – $130 million.
The company expects a 2024 net loss of $203 million &#8211; $183 million, compared to the previous loss range of $314 million – $274 million, and an adjusted EBITDA of $180 million &#8211; $200 million compared to previous forecast of $140 million &#8211; $180 million.
Concurrently, Emergent BioSolutions announced that brincidofovir (brand name Tembexa for smallpox treatment) will be included in a trial conducted and sponsored by PANTHER, under the leadership of the Africa Centres for <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/g41789320/emergent-biosolutions-supports-new-clinical-trial-evaluating-the-safety-and-efficacy-of-brincidofo" rel="noreferrer noopener">Disease Control and Prevention</a>.
The study will evaluate the safety and efficacy of brincidofovir in treating mpox virus. The trial is scheduled to begin in the coming weeks in the Democratic Republic of Congo and neighboring countries.
Price Action: EBS stock is up 28.3% at $11.80 at last check Thursday.
Photo via Shutterstock
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/11/41816035/ralph-lauren-soars-as-q2-results-outpace-expectations-ceo-eyes-holiday-season-with-raised-revenue-g" target="_blank" rel="noreferrer noopener">Ralph Lauren Soars As Q2 Results Outpace Expectations—CEO Eyes Holiday Season With Raised Revenue Goals</a></li>
</ul>

Biotech

Earnings

Equities

Guidance

Health Care

Movers

Trading Ideas

General

Mpox Vaccine Player Emergent BioSolutions Stock Jumps On Upbeat Annual Forecast, Expects Smaller Losses In 2024

DA Davidson analyst Kurt Yinger maintains TopBuild (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BLD#NYSE">BLD</a>) with a Buy and lowers the price target from $460 to $450.

DA Davidson Maintains Buy on TopBuild, Lowers Price Target to $450

Argus Research analyst Joseph Bonner maintains Electronic Arts (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EA#NASDAQ">EA</a>) with a Buy and raises the price target from $161 to $183.

Argus Research Maintains Buy on Electronic Arts, Raises Price Target to $183

Craig-Hallum analyst Richard Shannon maintains IonQ (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IONQ#NYSE">IONQ</a>) with a Buy and raises the price target from $15 to $22.

IONQ

Craig-Hallum Maintains Buy on IonQ, Raises Price Target to $22

Moleculin Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MBRX#NASDAQ">MBRX</a>) is set to give its latest quarterly earnings report on Friday, 2024-11-08. Here's what investors need to know before the announcement.
Analysts estimate that Moleculin Biotech will report an earnings per share (EPS) of $-2.44. 
Investors in Moleculin Biotech are eagerly awaiting the company's announcement, hoping for news of surpassing estimates and positive guidance for the next quarter.
It's worth noting for new investors that stock prices can be heavily influenced by future projections rather than just past performance.
<h3>Overview of Past Earnings</h3>
In the previous earnings release, the company beat EPS by $0.61, leading to a 10.8% drop in the share price the following trading session.
Here's a look at Moleculin Biotech's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
<th>Q3 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-2.31</td>
<td>-3.53</td>
<td>-3.05</td>
<td>-3.60</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-1.70</td>
<td>-2.02</td>
<td>-5.09</td>
<td>-2.85</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-11.0%</td>
<td>-0.0%</td>
<td>-14.000000000000002%</td>
<td>-5.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2024/1731006266_0.png" alt="eps graph" />
<h3>Market Performance of Moleculin Biotech's Stock</h3>
Shares of Moleculin Biotech were trading at $2.36 as of November 06. Over the last 52-week period, shares are down 71.6%. Given that these returns are generally negative, long-term shareholders are likely upset going into this earnings release. 
<a href="https://www.benzinga.com/quote/MBRX/earnings">To track all earnings releases for Moleculin Biotech visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

MBRX

Insights Ahead: Moleculin Biotech's Quarterly Earnings

ANI Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANIP#NASDAQ">ANIP</a>) is preparing to release its quarterly earnings on Friday, 2024-11-08. Here's a brief overview of what investors should keep in mind before the announcement.
Analysts expect ANI Pharmaceuticals to report an earnings per share (EPS) of $1.07.
Anticipation surrounds ANI Pharmaceuticals's announcement, with investors hoping to hear about both surpassing estimates and receiving positive guidance for the next quarter.
New investors should understand that while earnings performance is important, market reactions are often driven by guidance.
<h3>Earnings History Snapshot</h3>
Last quarter the company beat EPS by $0.08, which was followed by a 9.92% drop in the share price the next day.
Here's a look at ANI Pharmaceuticals's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
<th>Q3 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.94</td>
<td>0.99</td>
<td>0.85</td>
<td>0.84</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>1.02</td>
<td>1.21</td>
<td>1</td>
<td>1.27</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-10.0%</td>
<td>3.0%</td>
<td>-1.0%</td>
<td>-4.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2024/1731006258_0.png" alt="eps graph" />
<h3>ANI Pharmaceuticals Share Price Analysis</h3>
Shares of ANI Pharmaceuticals were trading at $58.4 as of November 06. Over the last 52-week period, shares are up 12.64%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. 
<h3>Analyst Observations about ANI Pharmaceuticals</h3>
For investors, staying informed about market sentiments and expectations in the industry is paramount. This analysis provides an exploration of the latest insights on ANI Pharmaceuticals.
Analysts have given ANI Pharmaceuticals a total of 5 ratings, with the consensus rating being Neutral. The average one-year price target is $73.4, indicating a potential 25.68% upside.
<h3>Comparing Ratings Among Industry Peers</h3>
The following analysis focuses on the analyst ratings and average 1-year price targets of Tilray Brands, Collegium Pharmaceutical and Evolus, three prominent industry players, providing insights into their relative performance expectations and market positioning.
<ul>
<li>For Tilray Brands, analysts project an Neutral trajectory, with an average 1-year price target of $1.75, indicating a potential 97.0% downside.</li>
<li>The consensus outlook from analysts is an Buy trajectory for Collegium Pharmaceutical, with an average 1-year price target of $41.5, indicating a potential 28.94% downside.</li>
<li>The consensus outlook from analysts is an Buy trajectory for Evolus, with an average 1-year price target of $24.6, indicating a potential 57.88% downside.</li>
</ul>
<h3>Snapshot: Peer Analysis</h3>
Within the peer analysis summary, vital metrics for Tilray Brands, Collegium Pharmaceutical and Evolus are presented, shedding light on their respective standings within the industry and offering valuable insights into their market positions and comparative performance.

<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>ANI Pharmaceuticals</td>
<td>Neutral</td>
<td>18.44%</td>
<td>$80.34M</td>
<td>-0.59%</td>
</tr>
<tr>
<td>Tilray Brands</td>
<td>Neutral</td>
<td>13.05%</td>
<td>$59.71M</td>
<td>-1.13%</td>
</tr>
<tr>
<td>Collegium Pharmaceutical</td>
<td>Buy</td>
<td>7.18%</td>
<td>$90.81M</td>
<td>8.94%</td>
</tr>
<tr>
<td>Evolus</td>
<td>Buy</td>
<td>35.59%</td>
<td>$47.83M</td>
<td>-60.12%</td>
</tr>
</tbody>
</table>

Key Takeaway:
ANI Pharmaceuticals ranks in the middle for consensus rating among its peers. It is at the bottom for revenue growth. In terms of gross profit, it is at the top among its peers. However, for return on equity, it is at the bottom compared to its peers.
<h3>Discovering ANI Pharmaceuticals: A Closer Look</h3>
ANI Pharmaceuticals Inc develops, manufactures, and markets generic prescription pharmaceuticals. It manufactures liquid, powder, and oral solid dose products. Its areas of product development include narcotics, oncolytic, hormones and steroids, and complex formulations involving extended release and combination products. Some of its generic products include Erythromycin ethyl succinate, Esterified Estrogen with Methyltestosterone (EEMT), Etodolac Fenofibrate, Fluvoxamine, Hydrocortisone Enema and Vancomycin. Its geographical segments are the United States and Canada, of which the majority of its revenue comes from the United States.
<h3>A Deep Dive into ANI Pharmaceuticals's Financials</h3>
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
Revenue Growth: ANI Pharmaceuticals's remarkable performance in 3 months is evident. As of 30 June, 2024, the company achieved an impressive revenue growth rate of 18.44%. This signifies a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of -1.95%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): ANI Pharmaceuticals's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of -0.59%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): ANI Pharmaceuticals's ROA excels beyond industry benchmarks, reaching -0.29%. This signifies efficient management of assets and strong financial health.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.63.
<a href="https://www.benzinga.com/quote/ANIP/earnings">To track all earnings releases for ANI Pharmaceuticals visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ANIP

A Peek at ANI Pharmaceuticals's Future Earnings

InflaRx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IFRX#NASDAQ">IFRX</a>) is gearing up to announce its quarterly earnings on Friday, 2024-11-08. Here's a quick overview of what investors should know before the release.
Analysts are estimating that InflaRx will report an earnings per share (EPS) of $-0.28.
InflaRx bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.
New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
<h3>Earnings History Snapshot</h3>
Last quarter the company missed EPS by $0.05, which was followed by a 2.99% increase in the share price the next day.
Here's a look at InflaRx's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
<th>Q3 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.21</td>
<td>-0.24</td>
<td>-0.2</td>
<td>-0.25</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.26</td>
<td>-0.18</td>
<td>-0.3</td>
<td>-0.14</td>
</tr>
<tr>
<td>Price Change %</td>
<td>3.0%</td>
<td>0.0%</td>
<td>-3.0%</td>
<td>-14.000000000000002%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2024/1731006244_0.png" alt="eps graph" />
<h3>Stock Performance</h3>
Shares of InflaRx were trading at $1.53 as of November 06. Over the last 52-week period, shares are up 17.97%. Given that these returns are generally positive, long-term shareholders should be satisfied going into this earnings release. 
<a href="https://www.benzinga.com/quote/IFRX/earnings">To track all earnings releases for InflaRx visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

IFRX

Earnings Preview: InflaRx

Craig-Hallum analyst Greg Palm maintains Kornit Digital (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KRNT#NASDAQ">KRNT</a>) with a Buy and raises the price target from $27 to $33.

KRNT

Craig-Hallum Maintains Buy on Kornit Digital, Raises Price Target to $33

Delcath Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DCTH#NASDAQ">DCTH</a>) is set to give its latest quarterly earnings report on Friday, 2024-11-08. Here's what investors need to know before the announcement.
Analysts estimate that Delcath Systems will report an earnings per share (EPS) of $-0.22. 
The market awaits Delcath Systems's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter.
It's important for new investors to understand that guidance can be a significant driver of stock prices.
<h3>Overview of Past Earnings</h3>
During the last quarter, the company reported an EPS missed by $0.12, leading to a 4.93% drop in the share price on the subsequent day.
Here's a look at Delcath Systems's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
<th>Q3 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.36</td>
<td>-0.47</td>
<td>-0.51</td>
<td>-0.52</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.48</td>
<td>-0.45</td>
<td>-0.48</td>
<td>-1.14</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-5.0%</td>
<td>2.0%</td>
<td>10.0%</td>
<td>-24.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2024/1731006227_0.png" alt="eps graph" />
<h3>Market Performance of Delcath Systems's Stock</h3>
Shares of Delcath Systems were trading at $10.94 as of November 06. Over the last 52-week period, shares are up 274.92%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. 
<h3>Analyst Insights on Delcath Systems</h3>
For investors, staying informed about market sentiments and expectations in the industry is paramount. This analysis provides an exploration of the latest insights on Delcath Systems.
The consensus rating for Delcath Systems is Buy, derived from 2 analyst ratings. An average one-year price target of $21.5 implies a potential 96.53% upside.
<h3>Comparing Ratings Among Industry Peers</h3>
This comparison focuses on the analyst ratings and average 1-year price targets of Pulmonx, AngioDynamics and Zynex, three major players in the industry, shedding light on their relative performance expectations and market positioning.
<ul>
<li>The consensus outlook from analysts is an Buy trajectory for Pulmonx, with an average 1-year price target of $16.0, indicating a potential 46.25% upside.</li>
<li>Analysts currently favor an Buy trajectory for AngioDynamics, with an average 1-year price target of $13.33, suggesting a potential 21.85% upside.</li>
<li>Zynex is maintaining an Buy status according to analysts, with an average 1-year price target of $14.67, indicating a potential 34.1% upside.</li>
</ul>
<h3>Peers Comparative Analysis Summary</h3>
The peer analysis summary provides a snapshot of key metrics for Pulmonx, AngioDynamics and Zynex, illuminating their respective standings within the industry. These metrics offer valuable insights into their market positions and comparative performance.

<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Delcath Systems</td>
<td>Buy</td>
<td>1468.89%</td>
<td>$6.25M</td>
<td>-146.09%</td>
</tr>
<tr>
<td>Pulmonx</td>
<td>Buy</td>
<td>15.39%</td>
<td>$15.03M</td>
<td>-14.50%</td>
</tr>
<tr>
<td>AngioDynamics</td>
<td>Buy</td>
<td>-14.22%</td>
<td>$36.72M</td>
<td>-6.36%</td>
</tr>
<tr>
<td>Zynex</td>
<td>Buy</td>
<td>0.10%</td>
<td>$39.79M</td>
<td>6.95%</td>
</tr>
</tbody>
</table>

Key Takeaway:
Delcath Systems ranks first in revenue growth among its peers. It has the lowest gross profit margin. Delcath Systems has the lowest return on equity.
<h3>Delving into Delcath Systems's Background</h3>
Delcath Systems Inc is an oncology company. It is focused on the treatment of primary and metastatic liver cancers. The firm's product, Melphalan Hydrochloride for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.
<h3>Breaking Down Delcath Systems's Financial Performance</h3>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Revenue Growth: Over the 3 months period, Delcath Systems showcased positive performance, achieving a revenue growth rate of 1468.89% as of 30 June, 2024. This reflects a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: Delcath Systems's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of -176.94%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Delcath Systems's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of -146.09%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of -39.25%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: Delcath Systems's debt-to-equity ratio is below the industry average. With a ratio of 1.33, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<a href="https://www.benzinga.com/quote/DCTH/earnings">To track all earnings releases for Delcath Systems visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

DCTH

Uncovering Potential: Delcath Systems's Earnings Preview

DA Davidson analyst Wyatt Swanson maintains Duolingo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DUOL#NASDAQ">DUOL</a>) with a Buy and raises the price target from $250 to $350.

DUOL

DA Davidson Maintains Buy on Duolingo, Raises Price Target to $350

Over the past 24 hours, Mantle's (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">MNT</a>) price has risen 14.54% to $0.68. This continues its positive trend over the past week where it has experienced a 12.0% gain, moving from $0.60 to its current price. As it stands right now, the coin's all-time high is $1.54. 
The chart below compares the price movement and volatility for Mantle over the past 24 hours (left) to its price movement over the past week (right). The gray bands are Bollinger Bands, measuring the volatility for both the daily and weekly price movements. The wider the bands are, or the larger the gray area is at any given moment, the larger the volatility.
<img src="https://www.benzinga.com/files/images/story/2024/1731006220_0.png" alt="price_chart" />
Mantle's trading volume has climbed 85.0% over the past week, moving in tandem, directionally, with the overall circulating supply of the coin, which has increased 0.35%. This brings the circulating supply to 3.37 billion, which makes up an estimated 54.14% of its max supply of 6.22 billion. According to our data, the current market cap ranking for MNT is #48 at $2.28 billion.
<img src="https://www.benzinga.com/files/images/story/2024/1731006221_1.png" alt="supply_and_vol" />
<a href="https://www.coingecko.com/en/api">Powered by CoinGecko API</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Markets

$MNT

Cryptocurrency Mantle's Price Increased More Than 14% Within 24 hours

CompoSecure (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMPO#NASDAQ">CMPO</a>) is preparing to release its quarterly earnings on Friday, 2024-11-08. Here's a brief overview of what investors should keep in mind before the announcement.
Analysts expect CompoSecure to report an earnings per share (EPS) of $0.29.
CompoSecure bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.
New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
<h3>Overview of Past Earnings</h3>
Last quarter the company beat EPS by $0.02, which was followed by a 29.16% increase in the share price the next day.
Here's a look at CompoSecure's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
<th>Q3 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.25</td>
<td>0.25</td>
<td>0.23</td>
<td>0.25</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.27</td>
<td>0.25</td>
<td>0.26</td>
<td>0.24</td>
</tr>
<tr>
<td>Price Change %</td>
<td>28.999999999999996%</td>
<td>4.0%</td>
<td>26.0%</td>
<td>-9.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2024/1731006214_0.png" alt="eps graph" />
<h3>Tracking CompoSecure's Stock Performance</h3>
Shares of CompoSecure were trading at $15.48 as of November 06. Over the last 52-week period, shares are up 207.39%. Given that these returns are generally positive, long-term shareholders should be satisfied going into this earnings release. 
<a href="https://www.benzinga.com/quote/CMPO/earnings">To track all earnings releases for CompoSecure visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CMPO

A Look at CompoSecure's Upcoming Earnings Report

Holley (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HLLY#NYSE">HLLY</a>) is preparing to release its quarterly earnings on Friday, 2024-11-08. Here's a brief overview of what investors should keep in mind before the announcement.
Analysts expect Holley to report an earnings per share (EPS) of $0.03.
Investors in Holley are eagerly awaiting the company's announcement, hoping for news of surpassing estimates and positive guidance for the next quarter.
It's worth noting for new investors that stock prices can be heavily influenced by future projections rather than just past performance.
<h3>Past Earnings Performance</h3>
In the previous earnings release, the company missed EPS by $0.00, leading to a 1.88% drop in the share price the following trading session.
Here's a look at Holley's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
<th>Q3 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.1</td>
<td>0.05</td>
<td>0.02</td>
<td>0.03</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.1</td>
<td>0</td>
<td>0</td>
<td>0.03</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-2.0%</td>
<td>-1.0%</td>
<td>-0.0%</td>
<td>-7.000000000000001%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2024/1731006187_0_0.png" alt="eps graph" />
<h3>Stock Performance</h3>
Shares of Holley were trading at $2.84 as of November 06. Over the last 52-week period, shares are down 27.08%. Given that these returns are generally negative, long-term shareholders are likely upset going into this earnings release. 
<h3>Analysts' Take on Holley</h3>
Understanding market sentiments and expectations within the industry is crucial for investors. This analysis delves into the latest insights on Holley.
With 3 analyst ratings, Holley has a consensus rating of Buy. The average one-year price target is $9.83, indicating a potential 246.13% upside.
<h3>Analyzing Ratings Among Peers</h3>
The analysis below examines the analyst ratings and average 1-year price targets of Stoneridge and Solid Power, three significant industry players, providing valuable insights into their relative performance expectations and market positioning.
<ul>
<li>The prevailing sentiment among analysts is an Outperform trajectory for Stoneridge, with an average 1-year price target of $16.0, implying a potential 463.38% upside.</li>
<li>For Solid Power, analysts project an Underperform trajectory, with an average 1-year price target of $1.0, indicating a potential 64.79% downside.</li>
</ul>
<h3>Snapshot: Peer Analysis</h3>
The peer analysis summary presents essential metrics for Stoneridge and Solid Power, unveiling their respective standings within the industry and providing valuable insights into their market positions and comparative performance.

<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Holley</td>
<td>Buy</td>
<td>-3.29%</td>
<td>$70.29M</td>
<td>3.77%</td>
</tr>
<tr>
<td>Stoneridge</td>
<td>Outperform</td>
<td>-10.22%</td>
<td>$44.49M</td>
<td>-2.61%</td>
</tr>
<tr>
<td>Solid Power</td>
<td>Underperform</td>
<td>3.44%</td>
<td>$-362K</td>
<td>-4.76%</td>
</tr>
</tbody>
</table>

Key Takeaway:
Holley is positioned at the top for Revenue Growth among its peers. It ranks in the middle for Gross Profit. Holley is at the top for Return on Equity.
<h3>Unveiling the Story Behind Holley</h3>
Holley Inc is a designer, marketer, and manufacturer of high-performance automotive aftermarket products, featuring a portfolio of iconic brands serving the car and truck industry. It offers a diversified line of performance automotive products including fuel injection systems, tuners, exhaust products, carburetors, safety equipment and various other performance automotive products. The Company's products are designed to enhance street, off-road, recreational and competitive vehicle performance through increased horsepower, torque and drivability. The company's brands include Holley, APR, MSD and Flowmaster, among others. It derives revenue from the U.S. and Italy, of which prime revenue is derived from the U.S.
<h3>Holley: Financial Performance Dissected</h3>
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
Decline in Revenue: Over the 3 months period, Holley faced challenges, resulting in a decline of approximately -3.29% in revenue growth as of 30 June, 2024. This signifies a reduction in the company's top-line earnings. When compared to others in the Consumer Discretionary sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Holley's net margin is impressive, surpassing industry averages. With a net margin of 10.09%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Holley's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 3.77%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): Holley's ROA excels beyond industry benchmarks, reaching 1.43%. This signifies efficient management of assets and strong financial health.
Debt Management: The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of 1.21, caution is advised due to increased financial risk.
<a href="https://www.benzinga.com/quote/HLLY/earnings">To track all earnings releases for Holley visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

HLLY

What's Next: Holley's Earnings Preview

U.S. stocks traded higher toward the end of trading, with the Nasdaq Composite gaining more than 200 points on Thursday.
The Dow traded up 0.03% to 43,743.75 while the NASDAQ rose 1.30% to 19,231.18. The S&amp;P 500 also rose, gaining, 0.63% to 5,966.19.
Check This Out: <a href="https://www.benzinga.com/news/24/11/41801967/top-3-energy-stocks-that-are-ticking-portfolio-bombs">Top 3 Energy Stocks That Are Ticking Portfolio Bombs</a>
Leading and Lagging Sectors Communication services shares surged by 1.7% on Thursday.
In trading on Thursday, financials shares fell by 1.4%.
Top Headline
U.S. initial jobless claims rose by 3,000 from the previous week to 221,000 in the final week of October, in-line with market expectations.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>AppLovin Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APP#NASDAQ">APP</a>) shares shot up 43% to $241.00 after the company reported better-than-expected quarterly financial results.</li>
<li>Shares of Emergent BioSolutions Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EBS#NYSE">EBS</a>) got a boost, surging 26% to $11.58 after the company announced it evaluated the safety and efficacy of its new clinical trial of Brincidofovir in treating Mpox across Africa. PANTHER will conduct a clinical trial under The Leadership of Africa Centres for Disease Control and Prevention.</li>
<li>Dutch Bros Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BROS#NYSE">BROS</a>) shares were also up, gaining 34% to $46.72 following third-quarter earnings.</li>
</ul>
Equities Trading DOWN
<ul>
<li>DENTSPLY SIRONA Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XRAY#NASDAQ">XRAY</a>) shares dropped 26% to $17.65 after the company lowered its FY24 guidance and Leerink Partners downgraded the stock from Outperform to Market Perform.</li>
<li>Shares of Digital Turbine, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APPS#NASDAQ">APPS</a>) were down 49% to $1.66 after the company reported worse-than-expected second-quarter financial results.</li>
<li>CommScope Holding Company, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COMM#NASDAQ">COMM</a>) was down, falling 23% to $5.32 after the company reported worse-than-expected third-quarter financial results.</li>
</ul>
Commodities In commodity news, oil traded up 1.3% to $72.63 while gold traded up 1.1% at $2,705.70.
Silver traded up 1.8% to $31.89 on Thursday, while copper rose 4.3% to $4.4270.
Euro zone
European shares closed mostly higher today. The eurozone's STOXX 600 gained 0.62%, Germany's DAX gained 1.70% and France's CAC 40 rose 0.76%. Spain's IBEX 35 Index rose 0.65%, while London's FTSE 100 fell 0.32%.
The Bank of England cut its Bank Rate by 25bps to 4.75% at its recent meeting. Retail sales in the Eurozone rose 0.5% month-over-month in September versus a revised 1.1% gain in August. The HCOB Eurozone construction PMI climbed to 43.0 in October from 42.1 in the previous month.
The S&amp;P Global France construction PMI climbed to 42.2 in October from 37.9 in the prior month, while German construction PMI declined to 40.2 in October from 41.7 in the previous month.
Asia Pacific Markets
Asian markets closed mixed on Thursday, with Japan's Nikkei 225 falling 0.25%, Hong Kong's Hang Seng Index gaining 2.02%, China's Shanghai Composite Index gaining 2.57% and India's BSE Sensex falling 1.04%.
China&#8217;s trade surplus widened to $95.27 billion in October from $56.13 billion in the year-ago period. Foreign exchange reserves in Singapore increased to SGD 507.6 billion in October from SGD 499.7 billion in the prior month.
Economics
<ul>
<li>U.S. initial jobless claims rose by 3,000 from the previous week to 221,000 in the final week of October, in-line with market expectations.</li>
<li>U.S. nonfarm business sector labor productivity increased by 2.2% in the third quarter compared to a revised 2.1% gain in the prior three-month period.</li>
<li>Unit labor costs in the nonfarm business sector rose an annualized 1.9% during the third quarter compared to a revised 2.4% increase in the earlier period.</li>
<li>U.S. wholesale inventories fell by 0.2% month-over-month to $903.7 billion in September versus the preliminary reading of a 0.1% decline and compared to a 0.2% gain in the prior month.</li>
<li>U.S. natural-gas stocks rose by 69 billion cubic feet to 3.932 trillion cubic feet in the week ended Nov. 1.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/news/24/11/41805406/wall-streets-most-accurate-analysts-spotlight-on-3-industrials-stocks-with-over-5-dividend-yields">Wall Street&#8217;s Most Accurate Analysts Spotlight On 3 Industrials Stocks With Over 5% Dividend Yields</a></li>
</ul>

Eurozone

Commodities

Intraday Update

APPS

BROS

COMM

XRAY

Crude Oil Rises 1%; US Jobless Claims Increase To 221,000

The Russell 2000 Index, which tracks US small-cap companies, rose about 6% to near-record highs and recorded the largest single-day gain in two years. The astounding surge came in the wake of Donald Trump&#39;s victory in the presidential election. 
Analysts expect Trump&#39;s victory to lead to faster economic growth and more market-friendly policies. This is because Trump supports lower corporate tax rates, deregulation and other policies that favor domestic growth, all of which would provide more stimulus to the U.S. economy and benefit riskier assets. The anticipation of greater tariff barriers and a step to move manufacturing back home will drive small-cap stocks higher (read: <a href="https://www.zacks.com/stock/news/2365355/etfs-set-to-soar-on-trumps-presidential-victory" target="_blank">ETFs Set to Soar on Trump&#39;s Presidential Victory</a>). 
In order to tap this trend, investors should consider small-cap ETFs for diversified exposure across several sectors. We have highlighted five funds that have a Zacks ETF Rank #2 (Buy) each, suggesting their outperformance in the coming weeks. These are iShares Core S&amp;P Small-Cap ETF IJR, iShares Russell 2000 ETF IWM, Vanguard Small-Cap ETF VB, Schwab U.S. Small-Cap ETF SCHA and SPDR Portfolio S&amp;P 600 Small Cap ETF SPSM.
<h3>Corporate Tax Cuts</h3>
Trump recently proposed reducing the statutory corporate income tax rate from 21% to 15%. He also promised to extend tax cuts passed during his first term &mdash; set to expire at the end of next year. With reduced tax expenses, profits for smaller companies will grow.
<h3>Deregulation</h3>
Trump&#39;s administration is focused on deregulating many industries like energy and finance aiming to reduce the compliance costs, which businesses face. For small-cap companies, which often lack the financial resources of larger firms to manage regulatory compliance, reduced regulations mean lower operational costs. This shift will allow small-cap businesses to operate with increased profitability.
<h2>Protectionist Stance</h2>
Trump&#39;s proposed tariffs against major U.S. trading partners would boost the greenback. A strong dollar provides an edge to domestic-focused companies as small caps do not have much exposure to the international market. As such, Trump&#39;s protectionist stance will benefit domestic producers, as higher import tariffs raise costs for foreign competitors.
<h3>More Rate Cuts In The Cards</h3>
After initiating a 50-bps rate cut in September, the Fed is expected to cut interest rates further this year. As the pint-sized companies have a higher debt burden (mostly at floating rates), lower rates lead to reduced borrowing costs, helping small businesses expand their operations easily and resulting in increased profitability. This, in turn, stimulates economic growth. As small-cap companies are more domestically tied, these are poised to outperform when the economy improves.
<h3>Geopolitics</h3>
Small-cap stocks are considered safer and better plays if political issues or economic turmoil creep into the picture. Escalating tensions in the Middle East and the ongoing Russia-Ukraine war are driving the appeal for small-cap stocks.
<h3>ETFs Set To Explode</h3>
iShares Core S&amp;P Small-Cap ETF (ARCA:IJR)&nbsp; 
iShares Core S&amp;P Small-Cap ETF offers exposure to U.S. small-cap stocks and follows the S&amp;P SmallCap 600 Index. iShares Core S&amp;P Small-Cap ETF holds 662 stocks in its basket, with none accounting for more than 0.8% of the assets. Financials, industrials, consumer discretionary and information technology are the top four sectors with double-digit exposure each.&nbsp; 
iShares Core S&amp;P Small-Cap ETF is the largest and most popular ETF in the small-cap space, with AUM of $85.3 billion and an average daily volume of 3 million shares. The product charges investors 6 bps in annual fees. 
iShares Russell 2000 ETF (ARCA:IWM) 
iShares Russell 2000 ETF is the largest and most popular ETF in the small-cap space, with an AUM of $68.9 billion and an average daily volume of 33 million shares. It tracks the Russell 2000 Index and holds well-diversified 1,973 stocks in its basket. IWM has key holdings in financials, healthcare, industrials and information technology. 
iShares Russell 2000 ETF charges 19 bps in annual fees (read: <a href="https://www.zacks.com/stock/news/2364988/etf-strategies-to-consider-as-trump-nears-victory?art_rec=etfs-overview-zacks_news-ID05-txt-2364988" target="_blank">ETF Strategies to Consider as Trump Nears Victory</a>). 
Vanguard Small-Cap ETF (ARCA:VB)&nbsp; 
Vanguard Small-Cap ETF follows the CRSP US Small Cap Index and holds a basket of 1,384 stocks, with none holding more than 0.5% of the assets. Vanguard Small-Cap ETF is widely spread across various sectors, with industrials, consumer discretionary, financials, information technology and healthcare being the top five. 
Vanguard Small-Cap ETF has AUM of $60.5 billion and trades in a solid average daily volume of about 549,000 shares. VB charges 5 bps in fees per year from investors.&nbsp; 
Schwab U.S. Small-Cap ETF (ARCA:SCHA) 
Schwab U.S. Small-Cap ETF tracks the Dow Jones U.S. Small-Cap Total Stock Market Index, holding 1,745 stocks in its basket. Each security accounts for less than 0.3% of the assets. Schwab U.S. Small-Cap ETF is widely spread across sectors, with financials, industrials, health care, information technology and consumer discretionary having double-digit exposure each. 
Schwab U.S. Small-Cap ETF has AUM of $18 billion and sees a solid volume of around 1 million shares a day. It has an expense ratio of 0.04%.&nbsp; 
SPDR Portfolio S&amp;P 600 Small Cap ETF (ARCA:SPSM) 
SPDR Portfolio S&amp;P 600 Small Cap ETF follows the S&amp;P Small Cap 600 Index, holding 605 stocks in its basket. None of the firms make up more than 0.7% of the assets. SPDR Portfolio S&amp;P 600 Small Cap ETF is also widely spread out across sectors, with financials, industrials, consumer discretionary, information technology and healthcare having double-digit exposure each.&nbsp; 
SPDR Portfolio S&amp;P 600 Small Cap ETF has been able to manage $11.9 billion in its asset base and trades in a good volume of 1.3 million shares a day on average. SPSM charges 3 bps in annual fees.
<a href="https://www.zacks.com/stock/news/2366589/small-cap-etfs-set-to-explode-under-trump-presidency?cid=CS-BENZ-FT-etf_news_and_commentary-2366589">To read this article on Zacks.com click here.</a>

ETFs

Small-Cap ETFs Set To Explode Under Trump Presidency

Over the past 24 hours, OKB's (CRYPTO:OKB) price has risen 3.06% to $40.34. This continues its positive trend over the past week where it has experienced a 5.0% gain, moving from $38.23 to its current price. As it stands right now, the coin's all-time high is $73.80. 
The chart below compares the price movement and volatility for OKB over the past 24 hours (left) to its price movement over the past week (right). The gray bands are Bollinger Bands, measuring the volatility for both the daily and weekly price movements. The wider the bands are, or the larger the gray area is at any given moment, the larger the volatility.
<img src="https://www.benzinga.com/files/images/story/2024/1731006154_0.png" alt="price_chart" />
The trading volume for the coin has increased 170.0% over the past week while the overall circulating supply of the coin has increased 0.39% to over 60.00 million which makes up an estimated 20.0% of its max supply, which is 300.00 million. The current market cap ranking for OKB is #44 at $2.42 billion.
<img src="https://www.benzinga.com/files/images/story/2024/1731006154_1.png" alt="supply_and_vol" />
<a href="https://www.coingecko.com/en/api">Powered by CoinGecko API</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Cryptocurrency OKB's Price Increased More Than 3% Within 24 hours

Y-mAbs Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/YMAB#NASDAQ">YMAB</a>) is preparing to release its quarterly earnings on Friday, 2024-11-08. Here's a brief overview of what investors should keep in mind before the announcement.
Analysts expect Y-mAbs Therapeutics to report an earnings per share (EPS) of $-0.15.
Investors in Y-mAbs Therapeutics are eagerly awaiting the company's announcement, hoping for news of surpassing estimates and positive guidance for the next quarter.
It's worth noting for new investors that stock prices can be heavily influenced by future projections rather than just past performance.
<h3>Overview of Past Earnings</h3>
The company's EPS missed by $0.08 in the last quarter, leading to a 8.74% increase in the share price on the following day.
Here's a look at Y-mAbs Therapeutics's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
<th>Q3 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.13</td>
<td>-0.14</td>
<td>-0.20</td>
<td>-0.19</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.21</td>
<td>-0.15</td>
<td>-0.02</td>
<td>-0.18</td>
</tr>
<tr>
<td>Price Change %</td>
<td>9.0%</td>
<td>-21.0%</td>
<td>12.0%</td>
<td>10.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2024/1731006153_0.png" alt="eps graph" />
<h3>Performance of Y-mAbs Therapeutics Shares</h3>
Shares of Y-mAbs Therapeutics were trading at $15.69 as of November 06. Over the last 52-week period, shares are up 215.45%. Given that these returns are generally positive, long-term shareholders should be satisfied going into this earnings release. 
<h3>Analyst Insights on Y-mAbs Therapeutics</h3>
For investors, staying informed about market sentiments and expectations in the industry is paramount. This analysis provides an exploration of the latest insights on Y-mAbs Therapeutics.
The consensus rating for Y-mAbs Therapeutics is Outperform, derived from 7 analyst ratings. An average one-year price target of $21.0 implies a potential 33.84% upside.
<h3>Analyzing Analyst Ratings Among Peers</h3>
In this analysis, we delve into the analyst ratings and average 1-year price targets of and Avid Bioservices, three key industry players, offering insights into their relative performance expectations and market positioning.
<ul>
<li>Avid Bioservices is maintaining an Outperform status according to analysts, with an average 1-year price target of $12.17, indicating a potential 22.43% downside.</li>
</ul>
<h3>Peer Metrics Summary</h3>
The peer analysis summary presents essential metrics for and Avid Bioservices, unveiling their respective standings within the industry and providing valuable insights into their market positions and comparative performance.

<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Y-mAbs Therapeutics</td>
<td>Outperform</td>
<td>9.86%</td>
<td>$19.78M</td>
<td>-9.51%</td>
</tr>
<tr>
<td>Avid Bioservices</td>
<td>Outperform</td>
<td>6.49%</td>
<td>$5.71M</td>
<td>-9.26%</td>
</tr>
</tbody>
</table>

Key Takeaway:
Y-mAbs Therapeutics ranks higher than its peers in terms of Revenue Growth and Gross Profit, indicating stronger financial performance in these areas. However, it lags behind in terms of Return on Equity. Overall, Y-mAbs Therapeutics is positioned towards the top compared to its peers based on the provided metrics.
<h3>Delving into Y-mAbs Therapeutics's Background</h3>
Y-mAbs Therapeutics Inc is a commercial-stage biopharmaceutical company. It is mainly engaged in the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. DANYELZA, is the first FDA-approved product of the company which is a recombinant humanized immunoglobulin G, subtype 1k, or IgG1k, monoclonal antibody or mAb that targets ganglioside GD2, which is expressed in various neuroectoderm-derived tumors and sarcomas.
<h3>Financial Milestones: Y-mAbs Therapeutics's Journey</h3>
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
Revenue Growth: Y-mAbs Therapeutics's remarkable performance in 3 months is evident. As of 30 June, 2024, the company achieved an impressive revenue growth rate of 9.86%. This signifies a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Y-mAbs Therapeutics's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of -40.57%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of -9.51%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Y-mAbs Therapeutics's ROA stands out, surpassing industry averages. With an impressive ROA of -6.92%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: With a below-average debt-to-equity ratio of 0.01, Y-mAbs Therapeutics adopts a prudent financial strategy, indicating a balanced approach to debt management.
<a href="https://www.benzinga.com/quote/YMAB/earnings">To track all earnings releases for Y-mAbs Therapeutics visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

YMAB

Examining the Future: Y-mAbs Therapeutics's Earnings Outlook

Over the past 24 hours, Cronos's (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">CRO</a>) price has risen 9.17% to $0.09. This continues its positive trend over the past week where it has experienced a 25.0% gain, moving from $0.07 to its current price. As it stands right now, the coin's all-time high is $0.97. 
The chart below compares the price movement and volatility for Cronos over the past 24 hours (left) to its price movement over the past week (right). The gray bands are Bollinger Bands, measuring the volatility for both the daily and weekly price movements. The wider the bands are, or the larger the gray area is at any given moment, the larger the volatility.
<img src="https://www.benzinga.com/files/images/story/2024/1731006145_0.png" alt="price_chart" />
The trading volume for the coin has climbed 366.0% over the past week, moving opposite, directionally, with the overall circulating supply of the coin, which has decreased 0.71%. This brings the circulating supply to 27.09 billion. According to our data, the current market cap ranking for CRO is #43 at $2.50 billion.
<img src="https://www.benzinga.com/files/images/story/2024/1731006145_1.png" alt="supply_and_vol" />
<a href="https://www.coingecko.com/en/api">Powered by CoinGecko API</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$CRO

Cryptocurrency Cronos's Price Increased More Than 9% Within 24 hours

The gaming peripheral industry is evolving rapidly due to increasing internet penetration worldwide, in confluence with the introduction of gaming PCs and laptops. So, let's analyze Logitech International (LOGI) and Corsair Gaming (CRSR) to determine which gaming peripheral stock has the edge ahead of earnings. Read more... The global gaming peripherals market is driven by the growing number of gaming enthusiasts in conjunction with the rising popularity of e-sports tournaments. The industry is further aided by the popularity of e-sports and other games, which have led to the launch of specialized gaming keyboards and gamepads. 
The global gaming peripheral market is predicted to grow at a <a href="https://www.expertmarketresearch.com/reports/gaming-peripherals-market">CAGR of 10.3%</a> during 2024-2032.   
Moreover, based on the <a href="https://www.businessresearchinsights.com/market-reports/pc-gaming-peripheral-market-102969">rising need for a user-friendly interface</a>, availability of hardware in a small size, and rising popularity, gaming consoles are likely to see rapid growth in the near future. An increasing number of dedicated players worldwide is driving the need for an improved gaming experience.
Against this backdrop, let's compare two <a href="https://stocknews.com/category/technology-hardware/">Technology - Hardware</a> stocks, Logitech International S.A. (<a href="https://stocknews.com/stock/LOGI/">LOGI</a>) and Corsair Gaming, Inc. (<a href="https://stocknews.com/stock/CRSR/">CRSR</a>), to analyze which gaming peripheral stock has the edge ahead of their earnings.
The Case for Logitech International S.A. stock
Valued at $14.71 billion by market cap, Logitech International S.A. (<a href="https://stocknews.com/stock/LOGI/">LOGI</a>) designs, manufactures, and markets software-enabled hardware solutions that connect people to working, creating, gaming, and streaming worldwide. The company is based in Lausanne, Switzerland.
On August 19, 2024, LOGI announced that it has partnered with Aimlabs, a platform developed by State Space Labs, Inc., to introduce The Gauntlet. This exciting new competition was part of the Global Logitech G PLAYDAYS initiative and features over $100,000 in cash and prizes for participants.
LOGI's stock has gained 31.9% over the past year to close the last trading session at $89.12.
In terms of the trailing-12-month <a href="https://www.investopedia.com/terms/a/assetturnover.asp">asset turnover ratio</a>, LOGI's 1.24x is 99.4% higher than the 0.62x industry average. Likewise, its 15.18% trailing-12-month EBIT margin is 203.6% higher than the 5% industry average.
LOGI's net sales for the first quarter that ended June 30, 2024, came in at $1.09 billion, up 77.4% year-over-year. Its non-GAAP operating income rose 67% year-over-year to $182.44 million. Its non-GAAP net income increased 68.9% year-over-year to $174.63 million, and its non-GAAP net income per share grew 73.8% over the previous year's quarter to $1.13.
Street expects LOGI's revenue for the second quarter ending September 2024 to increase 5% year-over-year to $1.11 billion. Its EPS is expected to be $1.07 for the same quarter. Moreover, the company surpassed consensus revenue and EPS estimates in each of the trailing four quarters.
LOGI's strong fundamentals are reflected in its <a href="https://stocknews.com/powr-ratings/">POWR Ratings</a>. The stock has an overall B rating, equating to Buy in our proprietary rating system. The POWR Ratings are calculated by considering 118 distinct factors, with each factor weighted to an optimal degree.
LOGI has an A grade for Quality. It is ranked #14 out of 41 stocks in the <a href="https://stocknews.com/category/technology-hardware/">Technology - Hardware</a> industry.
<a href="https://stocknews.com/stock/LOGI/">Click here</a> for the additional POWR Ratings for LOGI (Value, Growth, Sentiment, Stability, and Momentum).
The Case for Corsair Gaming, Inc. stock
Valued at $731.11 million by market cap, Corsair Gaming, Inc. (<a href="https://stocknews.com/stock/CRSR/">CRSR</a>) designs, develops, markets, and sells gaming and streaming peripherals, components, and systems in the Americas, Europe, the Middle East, and the Asia Pacific.
CRSR's stock has declined 39.7% over the past three months to close the last trading session at $7.02.
In terms of the trailing-12-month gross profit margin, CRSR's 24.78% is 50.3% lower than the 49.85% industry average. Likewise, its 1.95% trailing-12-month EBITDA margin is 80.4% lower than the industry average of 9.97%.
CRSR's net revenue for the second quarter that ended June 30, 2024, declined 80.3% year-over-year to $261.30 million. The company's net loss and net loss per share attributable to common stockholders of CRSR came in at $23.51 million and $0.28, up significantly from the prior year's quarter, respectively.
Street expects CRSR's revenue for the quarter ending September 2024 to decline 16.7% year-over-year to $302.44 million. The company's EPS for the same quarter is expected to decline 53% year-over-year to $0.06. Moreover, the company has failed to surpass consensus EPS estimates in each of the trailing four quarters.
CRSR's bleak fundamentals are reflected in its POWR Ratings. The stock has an overall D rating, translating to a Sell in our proprietary rating system.
The stock has a D grade for Stability, Sentiment, and Quality. Within the same industry, CRSR is ranked #34.
In addition to the POWR Ratings I've just highlighted, you can see CRSR's ratings for Growth, Momentum, and Value <a href="https://stocknews.com/stock/CRSR/">here</a>.
Corsair (CRSR) vs. Logitech (LOGI): Which Gaming Peripheral Stock Has the Edge Ahead of Earnings?
The exponential rise in the popularity of esports and competitive gaming majorly drives the global gaming peripheral market. Professional and amateur gamers seek equipment that offers precision, responsiveness, and customization options to gain a competitive edge. Furthermore, the ever-evolving gaming landscape fuels a constant need for innovation in peripherals. 
Both LOGI and CRSR stand to capitalize on these burgeoning industry trends. However, LOGI's higher profitability and strong analysts' sentiments favor it as the better gaming stock pick.
Our research shows that the odds of success increase when one invests in stocks with an Overall Rating of Strong Buy or Buy. View all the top-rated stocks in the Technology - Hardware industry <a href="https://stocknews.com/category/technology-hardware/">here</a>.
What To Do Next?
43 year investment veteran, Steve Reitmeister, has just released his 2024 market outlook along with trading plan and top 11 picks for the year ahead.
<a href="https://report.stocknews.com/sign-up/stock-market-outlook-2024/?formplacement=artbotad_smo24_rep">2024 Stock Market Outlook &gt;</a>

<hr />
LOGI shares were trading at $89.19 per share on Monday afternoon, up $0.10 (+0.11%). Year-to-date, LOGI has declined -6.18%, versus a 21.13% rise in the benchmark S&amp;P 500 index during the same period.
<hr><div style="clear:both;"></div> <h2>About the Author: Nidhi Agarwal</h2> <img src='https:/wp-content/uploads/2023/03/Nidhi-Agarwal_Headshot-3.jpg' style="float:left; padding:5px;width:125px;">Nidhi is passionate about the capital market and wealth management, which led her to pursue a career as an investment analyst. She holds a bachelor's degree in finance and marketing and is pursuing the CFA program.

Her fundamental approach to analyzing stocks helps investors identify the best investment opportunities.<a href="https://stocknews.com/authors/?author=nidhi-agarwal">More...</a>The post <a href=https://stocknews.com/news/logi-crsr-corsair-crsr-vs-logitech-logi-which-gaming-peripheral-stock-has/>Corsair (CRSR) vs. Logitech (LOGI): Which Gaming Peripheral Stock Has the Edge Ahead of Earnings?</a> appeared first on <a href=https://stocknews.com/>StockNews.com</a>

Corsair (CRSR) vs. Logitech (LOGI): Which Gaming Peripheral Stock Has the Edge Ahead of Earnings?

Logitech: Growth Tailwinds With Upside In Valuation

Corsair Gaming: May Be Worth A Second Look, A 'Buy' From Me

September videogame sales down 6% in the U.S., led by sharp drop in console spends

Corsair Gaming Non-GAAP EPS of -$0.29 misses by $0.35, revenue of $304.2M beats by $1.69M

Corsair Gaming, Inc. (CRSR) Q3 2024 Earnings Call Transcript

Corsair Gaming, Inc. ( ($CRSR) ) has released its Q3 earnings. Here is a breakdown of the information Corsair Gaming, Inc. presented to its investo...

Corsair Gaming Announces Q3 2024 Financial Results

Barclays analyst George Wang CFA maintained a Buy rating on Corsair Gaming (CRSR – Research Report) today and set a price target of $9.00. The comp...

Corsair Gaming (CRSR) Receives a Buy from Barclays

Barclays lowered the firm's price target on Corsair Gaming (CRSR) to $9 from $14 and keeps an Overweight rating on the shares. The firm says lower ...

Corsair Gaming price target lowered to $9 from $14 at Barclays

Freshworks, IonQ among tech stocks soaring after earnings, while Dynatrace dips

APPN

CCOEF

CCOEY

CRSR

ESPO

FRSH

GAMR

HEAR

KNAMF

KONMY

LOGI

MSFT

NCBDF

NCBDY

NERD

NEXOF

NEXOY

NTDOF

NTDOY

NTES

RBLX

SGAMF

SGAMY

SKLZ

SONY

SQNNY

SQNXF

TCEHY

TCTZF

TTWO

UBSFF

UBSFY

Press Releases

Corsair Gaming to Report Q2 2024 Financial Results on August 1; Provides Preliminary Q2 2024 Results

Corsair Gaming Reports Q2 2024 Financial Results

Elgato Launches Stream Deck Studio; Collaboration with Bitfocus Brings Highly Popular Stream Deck to Professional Broadcasters

Corsair Set to Acquire the Fanatec Product Line from Endor AG

CORSAIR Announces Exclusive Multi-Year, Cross Brand Partnership with Call of Duty® Franchise

Corsair Closed Acquisition of the Fanatec Product Line from Endor AG; Moves into Sim Racing's Pole Position

CORSAIR Launches High-Performance Products in Multi-Year, Cross Brand Collaboration with Call of Duty®

CORSAIR Launches VIRTUOSO MAX Headset with Active Noise Cancellation and Dolby Atmos for Ultra-Immersive Gaming; Available in Both PC and Xbox Versions

Comments

Corsair Gaming

Noticias

Últimas noticias sobre Corsair Gaming (NASDAQ:CRSR) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL